Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
Year: 2019
Type: review
Study designs: Systematic Review, Meta-Analysis
Source: The Lancet Oncology
Authors: Mario Giuliano, Francesco Schettini, Carla Rognoni, Manuela Milani, Guy Jerusalem, Thomas Bachelot, Michelino De Laurentiis, Guglielmo Thomas, Pietro De Placido, Grazia Arpino, Sabino De Placido, Massimo Cristofanilli, Antonio Giordano, Fabio Puglisi, Barbara Pistilli, Aleix Prat, Lucia Del Mastro, Sergio Venturini, Daniele Generali
Institutions: Baylor College of Medicine, Federico II University Hospital, University of Naples Federico II, Solti, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Bocconi University, Azienda Socio Sanitaria Territoriale di Cremona, Centre Hospitalier Universitaire de Liège, Centre Léon Bérard, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Clinica Mediterranea, Northwestern University, Medical University of South Carolina, University of Udine, Centro di Riferimento Oncologico, Institut Gustave Roussy, Hospital Clínic de Barcelona, Ospedale Policlinico San Martino, University of Genoa, University of Turin, University of Trieste
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: hormone receptor-positive HER2-negative metastatic breast cancer, postmenopausal women, endocrine therapy, chemotherapy, first-line therapy, second-line therapy, CDK4/6 inhibitors, palbociclib, ribociclib, abemaciclib, letrozole, fulvestrant, anastrozole, progression-free survival, overall response, targeted therapy
Open Access status: green
OpenAlex ID: W2972049666
